Views & Analysis New IFPMA and EFPIA guidance on use of social media by the p... On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.